HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Abstract
Vemurafenib, a RAF inhibitor, extends survival in patients with BRAF(V600)-mutant melanoma but activates extracellular signal-regulated kinase (ERK) signaling in RAS-mutant cells. In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. We hypothesized that combining vemurafenib with a MAP-ERK kinase (MEK) inhibitor would inhibit ERK activation in the melanoma and prevent ERK activation by vemurafenib in the leukemia, and thus suppress both malignancies. We demonstrate that intermittent administration of vemurafenib led to a near-complete remission of the melanoma, and the addition of the MEK inhibitor cobimetinib (GDC-0973) caused suppression of vemurafenib-induced leukemic proliferation and ERK activation. Antimelanoma and antileukemia responses have been maintained for nearly 20 months, as documented by serial measurements of tumor-derived DNA in plasma in addition to conventional radiographic and clinical assessments of response. These data support testing of intermittent ERK pathway inhibition in the therapy for both RAS-mutant leukemia and BRAF-mutant melanoma.
AuthorsOmar Abdel-Wahab, Virginia M Klimek, Alisa A Gaskell, Agnes Viale, Donavan Cheng, Eunhee Kim, Raajit Rampal, Mark Bluth, James J Harding, Margaret K Callahan, Taha Merghoub, Michael F Berger, David B Solit, Neal Rosen, Ross L Levine, Paul B Chapman
JournalCancer discovery (Cancer Discov) Vol. 4 Issue 5 Pg. 538-45 (May 2014) ISSN: 2159-8290 [Electronic] United States
PMID24589925 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Azetidines
  • DNA, Neoplasm
  • Indoles
  • Membrane Proteins
  • Piperidines
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • GTP Phosphohydrolases
  • NRAS protein, human
  • cobimetinib
Topics
  • Aged
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Azetidines (administration & dosage, therapeutic use)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • DNA, Neoplasm (analysis)
  • Drug Administration Schedule
  • GTP Phosphohydrolases (antagonists & inhibitors, genetics)
  • Humans
  • Indoles (administration & dosage, therapeutic use)
  • Leukemia (chemically induced, prevention & control)
  • MAP Kinase Signaling System (drug effects)
  • Male
  • Melanoma (drug therapy, genetics, pathology)
  • Membrane Proteins (antagonists & inhibitors, genetics)
  • Mutation
  • Neoplastic Cells, Circulating (drug effects)
  • Piperidines (administration & dosage, therapeutic use)
  • Proto-Oncogene Proteins B-raf (antagonists & inhibitors, genetics)
  • Sulfonamides (administration & dosage, therapeutic use)
  • Vemurafenib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: